Market research
JUBILANT.NSE Jubilant Life Sciences Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 145B
- P/E ratio
- 16.43
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 2.3
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE797F01012
- Market cap
- 145B
- P/E ratio
- 16.43
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 2.3
About
About Jubilant Life Sciences Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Drug Discovery & Development Solutions; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 49 radio pharmacies in the United States. The Drug Discovery & Development Solutions segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the JUBILANT.NSE discussion.
5 years, 5 months ago
Jubilant Pharmova Limited is currently in a long term downtrend where the price is trading 6.9% below its 200 day moving average.
From a valuation standpoint, the stock is 66.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Jubilant Pharmova Limited's total revenue sank by 18.2% to $8B since the same quarter in the previous year.
Its net income has increased by 3.5% to $760M since the same quarter in the previous year.
Based on the above factors, Jubilant Pharmova Limited gets an overall score of 2/5.